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Abstract
Background: Cytochrome-P450 (CYP450) epoxygenases metabolise arachidonic acid (AA) into four different
biologically active epoxyeicosatrienoic acid (EET) regioisomers. Three of the EETs (i.e., 8,9-, 11,12- and 14,15-EET) are
rapidly hydrolysed by the enzyme soluble epoxide hydrolase (sEH). Here, we investigated the role of sEH in
nociceptive processing during peripheral inflammation.
Results: In dorsal root ganglia (DRG), we found that sEH is expressed in medium and large diameter neurofilament
200-positive neurons. Isolated DRG-neurons from sEH-/- mice showed higher EET and lower DHET levels. Upon AA
stimulation, the largest changes in EET levels occurred in culture media, indicating both that cell associated EET
concentrations quickly reach saturation and EET-hydrolyzing activity mostly effects extracellular EET signaling. In
vivo, DRGs from sEH-deficient mice exhibited elevated 8,9-, 11,12- and 14,15-EET-levels. Interestingly, EET levels did
not increase at the site of zymosan-induced inflammation. Cellular imaging experiments revealed direct calcium
flux responses to 8,9-EET in a subpopulation of nociceptors. In addition, 8,9-EET sensitized AITC-induced calcium
increases in DRG neurons and AITC-induced calcitonin gene related peptide (CGRP) release from sciatic nerve
axons, indicating that 8,9-EET sensitizes TRPA1-expressing neurons, which are known to contribute to mechanical
hyperalgesia. Supporting this, sEH-/- mice showed increased nociceptive responses to mechanical stimulation
during zymosan-induced inflammation and 8,9-EET injection reduced mechanical thresholds in naive mice.
Conclusion: Our results show that the sEH can regulate mechanical hyperalgesia during inflammation by
inactivating 8,9-EET, which sensitizes TRPA1-expressing nociceptors. Therefore we suggest that influencing the
CYP450 pathway, which is actually highly considered to treat cardiovascular diseases, may cause pain side effects.
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Background
Inflammatory responses after tissue damage or infection
cause the release of arachidonic acid (AA) and its subse-
quent metabolism to biologically active lipids in acti-
vated immune cells and hyperactive neurons [1]. Free
AA is a major substrate for cyclooxygenases (COX),
lipoxygenases (LOX) and cytochrome P450 (CYP450)
epoxygenases which metabolize it to prostanoids, leuko-
trienes and epoxyeicosatrienoic acids (EETs) and hydro-
xyeicosatetranoic acids (HETES), respectively [2-4]. At
the site of injury and in the CNS prostanoids and
leukotrienes are inflammatory and pain mediators that
attract and activate immune cells as well as directly sen-
sitize nociceptive neurons [5,6].
Recently, those EETs involved in vascular homeostasis
and coronary physiology have been shown also to influ-
ence nociceptive processing [7,8]. EETs either bind
intracellular targets, are released to act as auto- or para-
crine mediators or are stored in cell membranes esteri-
fied to phospholipids [9]. They activate PPARg or the
cAMP/PKA pathway and modulate and/or activate a
variety of channels including several transient receptor
potential (TRP) channel isoforms, large-conductance
Ca2+-activated K+ channels (BK(Ca)) and L-type voltage
gated calcium channels (Ca(v)) [9].
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Three EETs (8,9-, 11,12- and 14,15-EET) are metabo-
lized by soluble epoxide hydrolase (sEH) to their corre-
sponding dehydro metabolites (DHET), which are
thought to be less active [10]. Increasing EET bioavail-
ability by blocking sEH activity or expression can be
used to study the actions of EETs in vivo. sEH inhibi-
tion strongly reduces nociceptive responses, suppresses
COX-2 expression and up-regulates the acute neuro-
steroid-producing gene StARD1, when applied either
topically to the inflammation site or injected intrathe-
cally in a model of inflammatory and neuropathic pain
[11,12]. Furthermore, a conditional knockout of cyto-
chrome P450 reductase (CRP) in CNS neurons, which
blocks CYP450 activity, largely abolishes morphine-
induced anti-nociception, suggesting that EETs have an
anti-nociceptive activity downstream of the μ-opioid
receptor [7].
EETs can however, directly activate TRPV4 channels
as well as elicit rapid membrane insertion of TRPV4
and TRPC6 channels [13-15] which may be pro-noci-
ceptive. In DRG-neurons, calcium influx after TRP-
channel opening leads to activation of signaling mole-
cules like p38 mitogen-activated protein-kinase, which
sensitize the neurons for further excitation [16].
TRPV4 and TRPC6, as other TRP- family channels
including, TRPV1 and TRPA1, mediate thermal and
mechanical hyperalgesia in various disease models
[17,18]. However, the mechanism how they are acti-
vated by specific endogenous agonists is largely
unknown.
We have now investigated EETs in nociceptive proces-
sing by phenotyping mice with targeted deletion of sEH,
and find that the EETs metabolized by sEH sensitize
TRPA1 expressing DRG neurons and that sEH-/- mice
show an increased mechanical hyperalgesia.
Results
sEH is expressed in primary afferent neurons
To determine if and how sEH could potentially contri-
bute to nociceptive processing we first analysed the cel-
lular distribution of sEH by Western blotting and
immunohistochemistry in edematous paw and DRG tis-
sue up to 48 h after an intraplantar zymosan injection.
Western blotting of tissue from wild- type mice revealed
a 58 kDa band which corresponds to the predicted size
of sEH but was not regulated in paw or DRG tissue
(Figure 1A). The band was specific for sEH, since it was
absent in the sEH-/- animals (Figure 1B). Comparison of
tissue sections from wild- type and sEH-/- animals by
immunohistochemistry showed specific sEH staining in
the DRG (Figure 1C). Notably, the distribution and loca-
lization of sEH immunoreactivity was not altered in
DRGs after zymosan treatment (Figure 1C). As indicated
by co-staining with NeuN, sEH expression in the DRG
was restricted to a subset of neurons. To determine
which cell types express sEH in DRGs, we combined
conventional immunohistochemistry with the Multi-epi-
tope ligand cartography-(MELC)-system which allows
repeated immunostaining using FITC-labelled primary
antibodies against several cell type-specific markers
[19,20]. We compared sEH expression with staining for
NeuN as a marker for all neurons, GFAP as a marker
for satellite glial cells, IB4 as a marker for unmyelinated
small diameter nociceptive neurons and NF200 as a
marker for myelinated medium and large diameter neu-
rons. The co-localisation pattern indicated that sEH is
predominantly expressed in NF200-positive neurons
(Figure 1D). These medium and large sized neurons
have myelinated axons forming Ab-and Aδ-fibers, with
the latter predominatly involved in fast nociception [21].
Further, a communication between innocuous Ab- and
noxious C- or Aδ-fibers can play a role in the develop-
ment of allodynia [22].
sEH activity in isolated DRG neurons and its contribution
to EET levels during inflammation
To investigate if sEH contributes to steady state EET
levels in vivo, we extracted lipids form DRG tissue of
naive wild type and sEH-/- mice. EET quantification by
LC-MS/MS analysis revealed that deletion of sEH
increased 8,9-EET, 11,12-EET and 14,15-EET tissue con-
centrations (Figure 2A) while 5,6-EET levels were unaf-
fected. DHETs were not detected in DRG tissue. To test
if sEH expression is regulated during peripheral inflam-
mation and if differences in EET levels become more
pronounced, we analysed DRG tissue samples 48h after
intraplantar zymosan injection. We found no difference
in 5,6-EET, 8,9-EET and 11,12-EET tissue concentra-
tions (Figure 2B). However, 14,15-EET concentrations
were reduced below the detection limit. We next inves-
tigated the functional contribution of sEH to EET
hydrolysis in DRG neurons by comparing basal EET
synthesis and that after stimulation with 0.5 μM AA in
DRGs from wild type and sEH deficient mice. In neuro-
nal cell lysates, we detected only a small increase in the
levels of some EETs, and only 8,9-EET was elevated in
sEH-/- compared to sEH+/+ cells (Figure 2C). However,
the level of DHET markedly increased when AA was
added, and this was significantly higher in wild type
than in sEH-/- cells (Figure 2D).
In contrast, we found dramatically elevated EET levels
(around 100-fold) after AA stimulation in the cell cul-
ture medium (Figure 2E). This indicates that cell asso-
ciated EET concentrations quickly reach saturation and
that higher AA availability increases EET release more
than its levels within neurons. Interestingly, the extracel-
lular DHET concentrations were strongly induced upon
AA stimulation, an effect which was markedly reduced
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in sEH-/- neurons (Figure 2F). These data suggest that
after increases in AA availability, EETs are released
from sensory neurons and that a deficiency in cellular
hydrolysis by deletion of sEH amplifies this effect.
Role of sEH on EET and prostaglandin levels at the
inflammation side
To elucidate if EET levels differ at the site of inflamma-
tion, we determined their levels in zymosan-inflamed
paws. First, we compared EET levels in wild- type mice
at the onset (1-2 h), peak (6 h) and recovery phases (24-
48 h) of inflammation after zymosan injection. We
found, no significant changes in EET levels up to 6
hours after zymosan injection (Figure 3A-C). However,
at later time points i.e., during the recovery phase, 8,9-
EET and 14,15-EET levels decreased significantly (Figure
3A, C). Next, we determined how EET levels were
altered by sEH deletion, 48 h after zymosan injection. In
d
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Figure 1 Expression pattern of sEH in primary afferent neurons. (A) Representative western blot analysis of sEH-expression during zymosan
induced inflammation in paw and DRG-tissue 0 - 48h after zymosan injection. (B) Western blot detection of sEH expression in tissues from
dorsal root ganglia and paw oedema tissue of wild type and sEH-deficient mice 48h after zymosan injection. Arrowhead indicates a signal
appearing only in wild- type tissue at approximately 58 kDa. (C) Expression pattern of sEH in dorsal root ganglia neurons. Immunofluorescence
staining of L4 or L5 dorsal root ganglia cryosections during zymosan induced inflammation (0h, 1h, 6h and 48h zymosan) was performed with
antibodies against sEH (green) and NeuN (red). At time point 48h post zymosan injection wildtype and sEH-deficient DRG-tissue were compared.
(D) Selective sEH expression in NF200 positive neurons. Combination of conventional immunofluorescence staining for sEH as in (C) with the
MELC technology using 7AAD and FITC-labeled primary antibodies against NeuN, glial fibrillary acidic protein (GFAP), isolectin B4 (IB4) and
neurofilament 200 (NF200).
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sEH-/- mice, 8,9- and 14,15-EET levels were significantly
increased while the corresponding DHETs were signifi-
cantly reduced (Figure 3D, E). 11,12-EET levels and 5,6-
EET were unaffected.
Recent studies suggest that sEH inhibition has an anti-
nociceptive effect in LPS-induced hyperalgesia and in
streptozocin-induced diabetic neuropathy [11,12,21,22].
One explanation for these findings is a direct anti-
inflammatory effect of the sEH inhibitors followed by
suppression of COX-2 expression in the inflamed paw
and spinal cord [10,11]. Since COX-2 is also strongly
upregulated in the zymosan model for up to 96 hours
[12] and hyperalgesia in this model strongly depends on
its activity [23,24], we examined COX-2 expression and
prostaglandin synthesis in the sEH-/- mice. However, 48
h after zymosan injection, a time point at which COX-2
expression remains upregulated in inflamed paws, no
differences in COX-2 expression or PGE2, PGD2, TXB2,
PGF2a or 6-keto-PGF1a levels at the site of inflamma-
tion or in the spinal cord were observed in wild type
and sEH knockout mice (Figure 3F-H).
Effects of EETs on nociceptive neurons
Next we determined whether increases in EET levels in
sensory ganglia after sEH deletion alters nociceptive
neurons. To do this, we applied 8,9-, 11,12- or 14-15-
EET to cultured DRG neurons and determined calcium
fluxes using fura-2-AM. At 1 μM none of the EETs
induced significant changes in intracellular calcium
levels. However, 10 μM 8,9-EET, but not 11,12- or 14-
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Figure 2 Contribution of sEH to EET release from sensory neurons and DRG tissue levels during inflammation. (A) Basal EET levels
extracted from tissues of DRGs from L4 and L5 segments from wild type and sEH deficient mice were determined by LC-MS/MS analysis. (B)
EET-tissue levels in DRGs 48h after intraplantar zymosan injection. Data shown represent the mean ± SEM from 6 animals. (C) EET and DHET (D)
levels in lysates of sensory neurons. Neuron enriched cultures from DRGs of wild- type and sEH-deficient mice were stimulated with 0.5 μM
arachidonic acid and incubated for 2 h until extraction of EETs from cells. Data shown represent the mean ± SEM from 5 culture dishes. (E) EET
and DHET (F) release from sensory neurons.. EETs were extracted from culture media of cells used in panel (C). Data shown represent the mean
± SEM from 5 culture dishes. Student’s t test: *, p ≤ 0.05; **, p ≤ 0.01.
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15-EET, increased intracellular calcium concentrations
when applied for 10 sec (Figure 4A, B). This calcium
transient was observed in 4.7% of all neurons as deter-
mined by the responsiveness of the cells to 40 mM KCl.
We further characterized the responding cells by co-sti-
mulation with menthol, capsaicin and AITC to identify
TRPM8, TRPV1 and TRPA1 expressing neurons respec-
tively (Figure 4C). 8,9-EET responding neurons were
predominantly capsaicin- and AITC-sensitive (92.3%)
showing that these cells are nociceptive neurons.
Next, we determined whether or not low concentra-
tions of 8,9-EET contribute to the sensitization of
nociceptive neurons. Therefore, we studied the effect of
1 μM 8,9-EET on AITC-induced calcium increases. We
found that 8,9-EET significantly increased the amplitude
of AITC evoked calcium increases in cultured DRG neu-
rons (Figure 5A, B). To further investigate nociceptor
activation by 8,9-EET, we measured the release of neu-
ropeptide from freshly isolated sciatic nerves [25].
TRPA1 channels are expressed along peptidergic nerve
fibers and neuropeptide release can be stimulated by
incubation with AITC [26]. To test, whether 8,9-EET
can sensitize neuropeptide release from those fibers, we
incubated sciatic nerves with 10 μM 8,9-EET or with
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Figure 3 Consequences of sEH deletion on EET and prostaglandin levels in the inflamed paw. (A-C) Changes in EET levels during
zymosan induced inflammation. Levels of 8,9- (A), 11,12-(B) and 14,15-EET (C) levels were determined by LC-MS/MS in paw tissues at different
time points after zymosan injection. (D) Changes in EET and DHET (E) levels after sEH deletion. Four different regioisomers were determined by
LC-MS/MS analysis in paw tissue from wild type and sEH-/- mice 48 h after intraplantar zymosan injection. Data shown represent the mean ±
SEM from tissues of 4-5 animals. Student’s t test: *, p ≤ 0.05. (F) Effect of sEH deletion on COX-2 expression. COX-2 protein levels were
determined by western blot in paw tissues from wild- type and sEH deficient mice 48 h after intraplantar zymosan injection. (G) Effect of sEH
deletion on prostaglandin synthesis in the inflamed paw. Prostaglandins were determined 48h after zymosan injection by LC-MS/MS analysis.
Data shown represent the mean ± SEM from tissues of 3-5 animals. (H) Effect of sEH deletion on prostaglandin synthesis in the spinal cord.
Prostaglandins were determined from lumbal spinal cord tissue 48h after zymosan injection. Data shown represent the mean ± SEM from tissues
of 4 animals.
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3.2% ethanol (vehicle) before stimulation with 50 μM
AITC. While 8,9-EET had no direct effect, it signifi-
cantly sensitized AITC-induced CGRP release from the
nerves (Figure 5C).
Effects of EETs and sEH deletion on nociceptive
thresholds during inflammation
TRPA1-expressing neurons appear to have an important
contribution to the development of mechanical hyperal-
gesia [27-29]. To test whether 8,9-EET, which activates
and sensitizes TRPA1-expressing neurons, also induces
mechanical hyperalgesia, we injected 10 μM of 8,9-EETs
intraplantarily and determined mechanical thresholds
using the Dynamic Plantar Aesthesiometer. Injection of
vehicle (3.2% ethanol (v/v)) reduced mechanical thresh-
olds 30 minutes after injection (Figure 6A). However,
this effect recovered after 1 hour while mice receiving
8,9-EET showed significantly lower mechanical
thresholds for up to 2 hours. In contrast, injections of
11,12- and 14,15-EET had no effect on nociceptive
behavior (Figure 6B).
Interestingly, after 8,9-EET injection we did not
detect any significant differences in thermal thresholds,
indicating that EETs affect noxious mechanical percep-
tions specifically (Figure 6C). To investigate the role of
sEH in nociceptive processing, we used the mice with
a targeted gene deletion of sEH, which exhibit much
higher 8,9-EET levels in DRGs after intraplantar injec-
tion of zymsoan A. Within the first 10 hours, wild type
and sEH-/- mice developed a comparable degree of
hyperalgesia (Figure 6D). However, from 24 to 96
hours after the zymosan-injection, sEH-deficient mice
exhibited strongly reduced mechanical thresholds com-
pared to the WT mice, indicating that deletion of sEH
prolongs mechanical hyperalgesia during peripheral
inflammation.
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Figure 4 Activation of primary afferent neurons by 8,9-EET. (A) 8,9-EET induces direct calcium influx in sensory neurons. Calcium
concentrations were monitored by ratiometric imaging using fura-2 in cultivated neurons from DRGs of adult wild- type mice. Shown is a
representative trace. 40 mM KCL solution was used to identify all viable neurons (B). Average values of peak normalized to baseline ratios of
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Figure 6 Effects of EETs and sEH deletion on mechanical pain thresholds. (A) 8,9-EET induces mechanical hyperalgesia. 20 μl of 10 μM 8,9-
EET was injected intraplantar and mechanical thresholds were determined by the Dynamic Plantar Test. Control animals received vehicle
solution containing the corresponding volumes of ethanol (3.2% v/v) and were tested in parallel. Data shown represent the mean ± SEM from 8
animals per group. Two way Anova with Bonferroni post test: *, p ≤ 0.05; **, p ≤ 0.01. (B) Same experiments than in (A) but other EET
regioisomers were used. (C) Thermal thresholds after 8,9-EET injection. 20 μl of 10 μM 8,9-EET or vehicle was injected and thermal thresholds
were determined by the Hargreaves test. Data shown represent the mean ± SEM from 4 animals. (D) Effect of sEH deletion on mechanical
hyperalgesia after zymosan injection. Mechanical thresholds of both hind paws were tested by the dynamic plantar test after unilateral
intraplantar zymosan injection and compared between sEH-/- mice and wild type C57BL/6 controls. Data shown represent the mean ± SEM from
8-9 animals per group. Two way ANOVA with Bonferroni post test: **, p ≤ 0.01.
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Taken together, these data suggests that 8,9-EET sen-
sitizes TRPA1 expressing primary afferent neurons and
that this may reduce mechanical thresholds. Moreover,
sEH-/- animals which have significantly elevated 8,9-
EET-levels in DRGs and paw show elevated mechanical
hyperalgesia during zymosan induced inflammation.
Discussion
In the present study we used a genetic mouse model to
characterise the role of sEH in nociceptive processing.
Our findings suggest that the sEH is expressed in a sub-
population of myelinated primary sensory neurons.
There, it negatively regulates steady state EET tissue
levels as well as release of EETs from neurons. Specifi-
cally we show that 8,9-EET activates TRPA1-expressing
neurons and sensitizes neuropetide release from
TRPA1-expressing fibers. Finally, we find that 8,9-EET
can induce mechanical hyperalgesia and that sEH dele-
tion prolongs mechanical hyperalgesia during
inflammation.
sEH exhibits lipid phosphatase as well as epoxide
hydrolase activity, with the latter resulting in rapid inac-
tivation of EETs and epoxyoctadecenoic acids (EpOMEs)
linoleic acid metabolites [11,30]. Although a putative
lipid phosphatase activity may have an impact on noci-
ceptive processing, we focused on the epoxide hydrolase
activity of sEH and on EETs/DHETs since they mediate
most sEH functions in the cardiovascular system [9,31].
The EETs are generally attributed with anti-inflamma-
tory effects, largely on the basis of the fact that 11,12-
EET can inhibit the IB kinase and NF-B signaling
[32]. However, although 11,12-EET appears to be the
most potent with respect to anti-inflammatory, anti-
migratory, and pro-fibrinolytic effects [33], it has also
been reported to increase COX2 expression in endothe-
lial cells, a phenomenon linked to angiogenesis [34].
This finding is of relevance, as one major consequence
of immune cell activation after zymosan injection is
induction of COX-2 expression at the inflammation site
and in the spinal cord to sensitize nociceptive proces-
sing [23,24]. However, we found no obvious change in
COX-2 expression or in prostaglandin synthesis in paw
tissue from zymosan-treated sEH-/- mice that could be
attributed to the higher EET levels in these animals.
Our results suggest that sEH deletion, which mainly
increases levels of 8-9- and 14,15-EET in the tissue stu-
died, does not alter zymosan-induced inflammatory
hyperalgesia by an inhibition of prostaglandin synthesis.
These findings contrast with those made by Incoeglu et
al. who described that inhibition of sEH reduces PGD2
synthesis and hyperalgesia in a LPS model [11]. While
these reports are difficult to reconcile, it is possible that
differences in the mechanisms of immune cell activation
between the two models may be a determinant factor
since LPS and zymosan selectively activate toll like
receptor 4 (TLR-4) and TLR-2, respectively [35] leading
to expression and release of a different set of proinflam-
matory mediators, which may be differentially affected
by EETs.
All studies reporting antinociceptive effects of sEH are
based on a pharmacological inhibition of the enzyme
[10,36,37]. The model used in the present investigation
was that of Ephx gene deletion resulting in the loss of
the N-terminal lipid phosphatase activity and C-terminal
soluble epoxide hydrolase activity. Thus, one major dif-
ference between our study and those performed pre-
viously is the fact that the sEH-associated lipid
phosphatase activity was also inhibited. As no endogen-
ous substrates or pharmacological inhibitors have been
identified that target sEH lipid phosphatase activity, it is
currently not possible to distinguish between the contri-
butions of the lipid phosphatase and the epoxide hydro-
lase activities to the phenotype of sEH-/- mice [38].
Another possible explanation for the differences
between this and previous studies could be related to
off-target effects of the urea-based inhibitors used in the
pharmacological studies. Although specificity for sEH
over other epoxide hydrolases such as mEH is generally
good for most inhibitors, some compounds including
12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA)
can also activate PPAR□, which represses COX-2
expression [39,40].
We did not detect the sEH in invading immune cells
within inflamed paw tissue. In contrast, we found pro-
minent expression of sEH in primary afferent neurons
in the DRG. It seems that also other components of the
EET generating/metabolising pathway are present in
sensory neurons. The epoxygenases CYP2J3 and CYP2J4
are expressed together with the sEH in trigeminal gang-
lia, indicating that the CYP450/sEH pathway is a com-
mon, integral component of peripheral sensory neuron
signaling [41].
In the nociceptive models used in this study mechani-
cal or heat stimuli are applied to the plantar surface of
the hind paw. Here, nociception is processed by small
and medium diameter DRG-neurons with C- and A-δ
fibres. We found that the sEH was mainly expressed in
NF200 positive large and medium diameter DRG neu-
rons. Most of these cells transmit proprioceptive and
low threshold mechanical but not noxious sensations.
However, we found that sEH deficient neurons have a
higher steady state release of EET into the extracellular
medium. Further, we showed that an increase of AA
bioavailability predominately affects EET release instead
of intracellular accumulation. This implies that the sEH
present in myelinated neurons may also affect C-fibre
neurons by paracrine signaling. Neuronal activity as well
as inflammation activates PLA2 in primary afferents
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causing increased synthesis of eicosanoids. The
restricted expression pattern of sEH in a subset of DRG
neurons and its hydrolyzing activity on EET, preventing
their release, suggests that the sEH may act to limit EET
signaling to nociceptors.
Using cellular imaging experiments we identified 8,9-
EET as the sEH substrate most likely to sensitize noci-
ceptor function. 8,9-EET induced a direct calcium influx
in ≈5% of sensory neurons. Co-stimulation with differ-
ent TRP-channel agonists revealed that 8,9-EET only
activates a subset of capsaicin responsive nociceptors
and not large non nociceptive neurons. Further, we
found that within the capsaicin-responsive group most
were also AITC-responsive (TRPA1-positive neurons)
(92.3% positive cells). Notably, Kwan et al. reported that
only AITC-sensitive neurons that also respond to
TRPV1 express TRPA1 [42]. Even though we did not
further address the specific target of 8,9-EET in this
TRPA1-expressing cell population, multiple studies have
shown that calcium transients in nociceptive neurons
induce plasticity changes through the activation of
PKCε, p38 MAPK or ERK which result in reduced acti-
vation thresholds and increased firing rates [43]. It
could be speculated that 8,9-EET may directly activate
TRPA1 at high concentrations although various other
possible targets exist. However, due to its electrophilic
character, 8,9-EET can potentially sensitize TRPA1 by
direct interaction with its intracellular cysteins as pre-
viously described for other lipids like 4-HNE or cyclo-
pentons [44,45]. In addition to a potential direct
activation of the TRPA1-positive cell population, we
found that lower doses of 8.9-EET potentiate AITC-
induced calcium flux. Here, 8,9-EET may modulate
TRPA1 indirectly via G-protein coupled receptors as
described for bradykinin [46]. Moreover, to increase
functionality of certain TRP-channels such as TRPC6,
EETs have already been shown to promote membrane
translocation [13]. Finally, other TRPA1 independent
downstream processes, such as sensitized voltage gated
calcium channels or calcium transporters may be
involved in the observed increased calcium responses.
We also investigated whether 8,9-EET modulates the
activation of TRPA1-expressing neurons. 8,9-EET appli-
cation to isolated sciatic nerves caused an increased
neuropeptide release in response to AITC. Peripheral
nerve axons resemble peripheral sensory terminals in
their common properties of sensory and signal transduc-
tion and CGRP neuropeptides are stored all along axons
of small diameter peptidergic neurons [47]. Stimulation
of those cells by AITC induces a translocation of
TRPA1 to the membrane where it can be activated
resulting in calcium influx, subsequent vesicle fusion
and neurotransmitter release. CGRP release from sciatic
nerves can be sensitized by activation of G-protein-
coupled receptors and related protein kinases [47] and
that CGRP can induce mechanical hyperalgesia and cen-
tral sensitization [48]. TRPA1 expressing neurons appear
to mediate mechanotransduction and blockade of
TRPA1 attenuates the development of mechanical
hyperalgesia [27,42,49]. Our finding that 8,9-EET
increases CGRP release from TRPA1 expressing neurons
strongly suggests that sEH activity in primary afferents
may prevents mechanical hypersensitivity.
In keeping with this, 8,9-EET injection into a hind
paw lowered the mechanical but not thermal threshold
in wild- type mice. Wild- type mice recover from zymo-
san-induced mechanical hyperalgesia 2 to 4 days after
injection, a time during which 8,9-EET levels decrease
in the paw tissue. Our finding that 8,9-EET sensitizes
primary afferents and reduces mechanical thresholds
suggested that hydrolysis of 8,9-EET could potentially
contribute to the resolution of mechanical hyperalgesia
during inflammation. In accordance with this hypoth-
esis, sEH-deficient mice, which exhibit elevated 8,9-EET
levels during inflammation, show a dramatically reduced
recovery from mechanical hyperalgesia.
Conclusion
sEH is expressed in sensory ganglia where it contributes
to the metabolism of 8,9-EET which can sensitize noci-
ceptors. As a consequence of genetic deletion of sEH
mice exhibit exaggerated hyperalgesia during inflamma-
tion underlining the importance of the antinociceptive
function sEH. Pharmacological interventions influencing
the EET-pathway, which are actually highly considered
to treat cardiovascular diseases, should therefore be
taken with care in terms of pain side effects.
Methods
Animals
sEH-/- mice [50] were crossbred for 10 generations onto
the C57BL/6 background. In all experiments the ethical
guidelines for investigations in conscious animals of the
NIH and International Association for the Study of Pain
were followed, and the procedures were approved by the
local Ethics Committee. sEH-/- mice were compared
with strain-, age-, and sex-matched C57BL/6 control
mice.
Behavioral tests
To determine mechanical hyperalgesia mice were kept
in test cages for 2 h on day one for habituation. On day
two, baseline paw withdrawal latencies (PWL) in
response to mechanical stimulation were determined.
Briefly, animals were placed on an elevated wire grid
and the plantar surface of the paw stimulated using a
Dynamic Plantar Aesthesiometer (Ugo Basile, Comerio
VA, Italy). We used a force increasing by 0.5 g every
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second with an upper limit of 5 g. Paw withdrawal
latencies were measured in sec ± 0.1 with a cut off of 20
sec.
To test the effects of EETs on mechanical hyperalge-
sia, 20 μl of either 8,9-, 11,12- or 14,15-EET (10 μM)
were injected subcutaneously into the mid plantar side
of the left hind paw. Control animals received a corre-
sponding volume of ethanol (3,2% v/v). Mechanical
hyperalgesia was assessed from 0.5 to 4 h after EET-
injection using the Dynamic Plantar Aesthesiometer.
Mechanical hyperalgesia after zymosan-induced
inflammation has been described previously [19,23]. 20
μl of a zymosan A (Sigma, Deisenhofen, Germany) sus-
pension (12.5 mg/ml in phosphate buffered saline) was
injected subcutaneously into the plantar side of one
hind paw. Mechanical hyperalgesia was assessed from
0.5 h to 96 h after zymosan injection using the Dynamic
Plantar Aesthesiometer as described above.
To exclude gender differences only male mice were
used. The non-injected and injected paws were mea-
sured alternately at intervals of 5-10 min. For all beha-
vioral tests the observer was unaware either of
genotypes or treatment.
Western blot analysis
For Western blot analysis we dissected skin tissue from
the mid-plantar region of the paw (1-3 mm deep) and
collected DRGs from L4-6 segments. Tissues were
homogenised and sonicated in PBS and whole cell
lysates containing 30 μg protein used for separation on
a 15% SDS-polyacrylamide gel. After blotting, COX-2
was detected with a polyclonal antibody (1:500) from
Cayman (Ann Arbor, MI). sEH was detected with a
polyclonal anti-mouse sEH antibody (dilution of 1:2000)
raised against recombinant murine sEH produced in a
baculovirus expression system, and then purified to
apparent homogeneity by affinity chromatography. Anti-
bodies against ß-actin (1:5000), HSP90 (1:2000) or ERK-
2 (1:500) (all from Santa Cruz, CA) were used to control
for loading.
Immunohistochemistry using Multi-epitope ligand
cartography (MELC)
DRGs and paws (48h after zymosan) were dissected
from mice intracardially perfused with 0.9% saline fol-
lowed by 4% PFA/PBS (pH 7.4). After 24 h incubation
in 30% sucrose/PBS the tissue was cryostat sectioned at
10 μm and stored at 4° C until use.
To analyse sEH expression we combined conventional
immunohistochemistry for sEH staining with the
MELC-technique using FITC-labelled antibodies against
cell type specific markers [19,20]. For sEH-staining we
blocked the slices with 10% BSA and 1% mouse serum
in PBS followed by a 15 h incubation with a polyclonal
rabbit anti sEH antibody (1:1000) diluted in the blocking
solution and a 1 h incubation with a anti-rabbit-Cy3
antibody (1:1000) (Sigma, Deisenhofen, Germany)
diluted in 1% BSA/PBS. To compare the sEH signal
between wt and sEH-/- mice the DRG slices were cost-
ained with NeuN and DAPI [23]. For comparison with
multiple markers the slices stained for sEH were then
transferred to the MELC-system. Here, we used mono-
clonal anti-neuronal nuclei (NeuN) (Millipore, Billerica,
MA), monoclonal anti NF200 (AbD Serotec, Oxford,
UK), monoclonal anti glial fibrillary acidic protein
(GFAP) (Sigma, Deisenhofen, Germany) and Isolectin
B4 (IB4) (Sigma, Deisenhofen, Germany) which were all
directly labelled with FITC as described [19,51].
Primary dorsal root ganglia (DRG)-cultures
DRGs were dissected from all spinal segments of adult
mice and transferred to ice cold HBSS with CaCl2 and
MgCl2 (Invitrogen, Carsbad, CA, USA). For dissociation,
isolated DRGs were treated for 90 min with collagenase/
dispase (500 U/ml collagenase; 2.5 U/ml dispase) fol-
lowed by a 20 minutes incubation with 0.05% Trypsin
(Invitrogen, Carsbad, CA, USA). After removal of the
enzyme-solutions, cells were washed twice with neuro-
basal medium containing 10% FCS respectively. Then
cells were mechanically dissociated by pipetting (Gilson
1000 μl) and plated on culture dishes or poly-l-lysine
(Sigma, Deisenhofen, Germany) coated glass cover slips
for calcium imaging. After two hours incubation, neuro-
basal medium containing 2 mM L-glutamine, 100 U/ml
penicillin, 100 μg/ml streptomycin, 50 μg/ml gentamicin
and supplement B27 (all from Invitrogen, Carsbad, CA,
USA) were added and cells incubated for 24-48 h at 37°
C without serum, NGF or any other neurotrophins.
Calcium imaging experiments
Calcium imaging experiments were performed on DRG
cultures 24 h to 48 h after preparation. Cells were
loaded with 5 μM Fura-2-AM-Ester containing 0.02%
Pluronic F-127 (both from Biotrend, Köln, Germany)
and incubated for 30 to 45 min at 37° C. For baseline
measurements extracellular solution (145 mM NaCl,1.25
mM CaCl2, 1 mM MgCl2, 5 mM KCl, 10 mM D-glu-
cose, 10 mM HEPES, pH 7.3) was added by bath appli-
cation at a flow-rate of 1-2 ml/min. EETs were dissolved
in the extracellular solution at a concentration of 1 and
10 μM. Cells were stimulated for 30 seconds. For con-
trol the corresponding volume of ethanol was applied in
the same way. At the end of each measurement, cells
were stimulated with 40 mM KCl for 30 seconds to
identify viable neurons. Images were taken with an
Axioscope 2 upright microscope (Zeiss, Jena, Germany)
using a 10x Achroplan water immersion objective
(Zeiss). The microscope was equipped with an Imago
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CCD camera, a Polychrome IV monochromator (all
TILL Photonics, Gräfelfing, Germany). Images were
acquired and processed using Tillvision software [52].
Quantitative characterization of 8,9-EET responding
cells was done using a Nikon Ti-E PFS Large Research
Microscope cells were recorded every 8 sec. with a
QImaging EXI Aqua Digital Camera (Q-imaging, Surrey,
BC, Canada) after alternating excitation with 340nm and
380nm by a Ti-FL Epi-Fluorescence Illuminator (Sutter
Instrument Company Novato, CA) regulated by a
SmartShutter Controller Unit (Sutter Instrument Com-
pany Novato, CA). Emission was filtered by an ET
FURA-2 Hybrid Filter. Extracellular solutions were
applied via a 360 μm perfusion pencil tip and a valve
bank control system (both from AutoMate scientific
inc., Berkeley, CA) with » 1 drop/sec gravity flow. Fluor-
escence intensities of single cells were calculated by the
NIS-Elements (AR Advance Research Acquisition and
analysis) software and transferred to Microsoft Excel for
further statistical analysis.
The DRG neurons were stimulated for 10 sec with 10
μM 8,9-EET, 200 μM menthol, 0.3 μM capsaicin, 100
μM AITC and 40 mM KCL. Neurons from 2 different
dissections and 6 different experiments were used for
calculations. For sensitization experiments, DRG cells
were stimulated with 50 μM AITC for 15 seconds twice
with an interval of 10 minutes. 1 μM 8,9-EET were per-
fused over the cells for two minutes prior to the second
AITC-stimulation.
Sciatic nerve CGRP-release measurements
The experimental procedures were performed exactly
as described before [47]. C57BL/6 mice were sacrificed
in CO2-. Sciatic nerves were excised and continuously
rinsed with synthetic interstitial fluid (SIF, Bretag,
1969) consisting (in mM) of 107.8 NaCl, 26.2 NaCO3,
9.64 Na-gluconate, 7.6 sucrose, 5.05 glucose, 3.48 KCl,
1.67 NaH2PO4, 1.53 CaCl2 and 0.69 MgSO4, gassed
with 95% oxygen and 5% carbon dioxide creating pH
7.4. Preparations were placed in SIF inside a thermo-
static shaking bath at 32°C for a 30 min washout-
phase before the experiment. All experiments were
performed with matched pairs of a treated and
untreated side from the same animal. An experiment
consisted of four incubations of 5 minutes in mesh
wells filled with 100 μl carbogen-saturated SIF. After
two incubations to determine basal CGRP release and
spontaneous variation at 32°C, the samples were stimu-
lated with AITC (50 μM). 10 μM 8,9-EET was added
in steps two to four. Immediately after removal of the
nerve from an incubation tube a sample volume of 100
μl was processed using a CGRP-EIA kit (SPIbio,
France) [53]. The CGRP detection level of the method
is ~2 pg/ml.
Determination of EETs and their metabolites by liquid
chromatography-tandem mass spectrometry (LC/MS-MS)
Sampling of tissue from DRGs and inflamed paws
For the determination of EETs and prostanoids during
inflammation, 20 μl of 10 mg/ml Zymosan A was
injected intraplantarily into hind paws of wild type and
sEH-deficient mice. At indicated time points, DRGs
from L4-6 segments and the tissue from the mid-plantar
region of the paw (1- 3 mm deepma) was dissected,
weighed and directly transferred to organic extraction
solvents including 20 μl internal standards (5,6 EET-
d11, 8,9 EET-d8, 11,12 EET-d8 and 14,15 EET-d8 all
with a concentration of 200 ng/ml in methanol) and
stored at -80° C. The next day, tissue samples were
homogenized in extraction solvents using a Retsch
Mixer-Mill MM 200 (Retsch, Haan, Germany).
Sampling of conditioned media from DRG cultures
For the determination of EET-release from sensory neu-
rons we used primary” DRG-neurons from wild type
and sEH-deficient mice. After 24 h in culture, cells were
stimulated with 0.5 μM arachidonic acid and incubated
for 2 h. Then, the cell culture supernatant was removed,
internal standards added, and samples directly extracted.
Sample extraction and standards
All standard substances were obtained from Cayman
Chemical, Ann Arbor, MI, USA. Stock solutions with
2500 ng/ml of all analytes were prepared in methanol.
Working standards were obtained by further dilution
with a concentration range of 0.1-250 ng/ml for EETs
respectively.
Sample extraction was performed with liquid-liquid-
extraction. Therefore tissue or cell culture medium was
extracted twice with ethyl acetate. The combined
organic phases were removed at a temperature of 45° C
under a gentle stream of nitrogen. The residues were
reconstituted with 50 μl of methanol/water/(50:50, v/v),
centrifuged for 2 minutes at 10,000x g and then trans-
ferred to glass vials (Macherey-Nagel, Düren, Germany)
prior to injection into the LC-MS/MS system. Extraction
and LC-MS/MS-instrumentation for measurment of
prostanoids was described previously [19,23].
Instrumentation for measuring 5,6-EET, 8,9-EET, 11,12-EET,
14,15-EET and their dehydro metabolites
The LC/MS-MS system comprised an API 4000 triple
quadrupole mass spectrometer (Applied Biosystems,
Darmstadt, Germany), equipped with a Turbo-V-source
operating in negative ESI mode, an Agilent 1100 binary
HPLC pump and degasser (Agilent, Waldbronn, Ger-
many) and an HTC Pal autosampler (Chromtech,
Idstein, Germany) fitted with a 25 μL LEAP syringe
(Axel Semrau GmbH, Sprockhövel, Germany). High
purity nitrogen for the mass spectrometer was produced
by a NGM 22-LC/MS nitrogen generator (cmc Instru-
ments, Eschborn, Germany).
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For the chromatographic separation a Gemini NX C18
column and precolumn were used (150 mm × 2 mm i.
d., 5 μm particle size and 110Å pore size from Phenom-
enex, Aschaffenburg, Germany). A linear gradient was
employed at a flow rate of 0.5 ml/min mobile phase
with a total run time of 17.5 minutes. Mobile phase A
was water/ammonia (100:0.05, v/v) and B acetonitrile/
ammonia (100:0.05, v/v).
The gradient started from 85% A to 10% within 12
min. This was held for 1 min at 10% A. Within 0.5 min
the mobile phase shifted back to 85% A and was held
for 3.5 min to equilibrate the column for the next sam-
ple. The injection volume of samples was 20 μl.
Quantification was performed with Analyst Software V
1.4.2 (Applied Biosystems, Darmstadt, Germany)
employing the internal standard method (isotope- dilu-
tion mass spectrometry). Ratios of analyte peak area and
internal standard area (y-axis) were plotted against con-
centration (x-axis) and calibration curves were calcu-
lated by least square regression with 1/concentration2
weighting.
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